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PRESERVED EJECTION FRACTIONThe Hospitalization Burden and
Post-Hospitalization Mortality Risk in
Heart FailureWith Preserved Ejection Fraction
Results From the I-PRESERVE Trial (Irbesartan in
Heart Failure and Preserved Ejection Fraction)Peter E. Carson, MD,* Inder S. Anand, MD, DPHIL (OXON),y Sithu Win, MD,y Thomas Rector, PHD,yMarkus Haass, MD,z
Jose Lopez-Sendon,MD,xAlanMiller,MD,jj JohnR. Teerlink,MD,{MichelWhite,MD,#Robert S.McKelvie,MD, PHD,**
Michel Komajda, MD,yy Michael R. Zile, MD,zz John J. McMurray, MD,xx Barry Massie, MD{ABSTRACTOBJECTIVES The aim of this study was to investigate prognosis in patients with heart failure (HF) with preserved
ejection fraction and the causes of hospitalization and post-hospitalization mortality.
BACKGROUND Although hospitalizations in patients with HF with preserved ejection fraction are common, there are
limited data from clinical trials on the causes of admission and the inﬂuence of hospitalizations on subsequent mortality risk.
METHODS Patients (n ¼ 4,128) with New York Heart Association functional class II to IV HF and left ventricular ejection
fractions >45% were enrolled in I-PRESERVE (Irbesartan in Heart Failure and Preserved Ejection Fraction). A blinded
events committee adjudicated cardiovascular hospitalizations and all deaths using predeﬁned and standardized deﬁni-
tions. The risk for death after HF, any-cause, or non-HF hospitalization was assessed using time-dependent Cox pro-
portional hazard models.
RESULTS A total of 2,278 patients had 5,863 hospitalizations during the 49 months of follow-up, of which 3,585 (61%)
were recurrent hospitalizations. For any-cause hospitalizations, 26.5% of patients died during follow-up, with an incident
mortality rate of 11.1 deaths per 100 patient-years (PYs) and an adjusted hazard ratio of 5.32 (95% conﬁdence interval:
4.21 to 6.23). Overall, 53.6% of hospitalizations were classiﬁed as cardiovascular and 43.7% as noncardiovascular, with
2.7% not classiﬁable. HF was the largest single cause of initial (17.6%) and overall (21.1%) hospitalizations, although,
after HF hospitalization, a substantially higher proportion of readmissions were due to primary HF causes (40%). HF
hospitalization occurred in 685 patients, with 41% deaths during follow-up, an incident mortality rate of 19.3 deaths per
100 PYs. The adjusted hazard ratio was 2.93 (95% conﬁdence interval: 2.40 to 3.57) relative to patients who were not
hospitalized for HF and was greater in those with longer durations of hospitalization. There were 1,593 patients with only
non-HF hospitalizations, 21% of whom died during follow-up, with an incident mortality rate of 8.7 deaths per 100 PYs
and an adjusted hazard ratio of 4.25 (95% conﬁdence interval: 3.27 to 5.32). The risk for death was highest in the ﬁrst
30 days and declined over time for all hospitalization categories. Patients not hospitalized for HF or for any cause had
observed incident mortality rates of 3.8 and 1.3 deaths per 100 PYs, respectively.
CONCLUSIONS In I-PRESERVE, HFpEF patients hospitalized for any reason, and especially for HF, were at high risk for
subsequent death, particularly early. The ﬁndings support the need for careful attention in the post-discharge time
period including attention to comorbid conditions. Among those hospitalized for HF, the high mortality rate and
increased proportion of readmissions due to HF (highest during the ﬁrst 30 days), suggest that this group would be an
appropriate target for investigation of new interventions. (J Am Coll Cardiol HF 2015;3:429–41) © 2015 by the American
College of Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
CV = cardiovascular
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
PY = patient-year
From the *
Affairs Hea
xHospital G
Affairs Me
Center, Mo
yyUniversit
University
Center, Gla
necessarily
resources a
Teerlink, W
reported th
Manuscrip
Carson et al. J A C C : H E A R T F A I L U R E V O L . 3 , N O . 6 , 2 0 1 5
Morbidity and Mortality in HFpEF J U N E 2 0 1 5 : 4 2 9 – 4 1
430A lthough heart failure (HF) with pre-served ejection fraction (HFpEF)represents a substantial proportion
of patients with HF, there remain gaps in
knowledge and also controversy regarding
this syndrome and its prognosis (1–3). There
is agreement that hospitalizations in patients
with HFpEF are common. However, although
cardiovascular (CV) hospitalizations have
been reported to account for the majority of
events, and HF is the most frequent primary
cause, other CV causes have not been wellcharacterized (4,5). Furthermore, although recurrent
hospitalizations in patients with HF are an important
clinical concern, as well as a performance metric,
there are no comprehensive reports of these events
in patients with HFpEF.SEE PAGE 442The controversy over prognosis involves mortality
in patients with HFpEF. Large registries and data-
bases, including a recent meta-analysis, have re-
ported that patients with HFpEF are at high mortality
risk (6–8). However, randomized clinical trials in pa-
tients with HFpEF have noted markedly lower mor-
tality rates (4,5,9,10), though still higher than those
noted in older subjects without HF enrolled in clinical
trials of hypertension or diabetes (11). How can these
varying event rates be explained? One explanation
may be that many HF registries enroll patients during
acute HF hospitalizations (6,7,12,13), whereas ran-
domized clinical trials of HFpEF have enrolled stable
outpatients. The inﬂuence of HF hospitalization on
mortality in clinical trials of HFpEF has not previ-
ously been reported. Furthermore, although many
patients with HFpEF have important comorbidities
and are commonly hospitalized for reasons other than
for HF, there are no data on the inﬂuence of non-HF
hospitalizations on prognosis.
Currently, because there is no proven therapy to
decrease the hospitalization burden or mortality inWashington Veterans Affairs Medical Center and Georgetown Uni
lth Care System and University of Minnesota, Minneapolis, Minne
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composition of events may aid in designing thera-
peutic strategies and clinical trials.
The I-PRESERVE (Irbesartan in Heart Failure and
Preserved Ejection Fraction) clinical trial is the largest
study of HFpEF to date (9,14). To evaluate the prog-
nosis in HFpEF, we examined the composition of ﬁrst
and recurrent CV hospitalizations. We also report on
the inﬂuence of hospitalizations on subsequent
mortality.
METHODS
The I-PRESERVE study design and results have been
previously described (9,14). Brieﬂy, 4,128 patients
with HF symptoms and left ventricular ejection frac-
tions of at least 45% were randomized to receive
either irbesartan or placebo. Patients eligible for
enrollment were required to have hospitalizations for
HF within the previous 6 months and at least New
York Heart Association functional class II symptoms
or corroborative evidence suggesting diastolic dys-
function and New York Heart Association functional
class III or IV symptoms. A clinical end point com-
mittee adjudicated all deaths and CV hospitalizations;
details of the mortality adjudications have been
published previously (15), and both these deﬁnitions
as well as those for hospitalizations are available in
the Online Appendix. The end point committee chair
reviewed all hospitalizations that were classiﬁed as
non-CV in serious adverse event reports, and possible
CV events were sent to the full committee. Hospital-
izations were deﬁned as admissions of at least 24 h in
duration or with calendar date changes if times of
admission or discharge were unavailable, and those
assessed as HF hospitalizations required speciﬁc
intravenous therapy or augmented oral medications
for that disease. Deaths were adjudicated as CV, non-
CV, or of unknown cause. The major CV death sub-
categories were sudden cardiac death and pump
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431deaths included those due to myocardial infarction,
stroke, CV procedures, vascular causes, and other
cardiac causes.
STATISTICAL ANALYSIS. Baseline characteristics of
patients were compared using 2-sample Student t tests
for continuous variables, and cross tabulations with
chi-square tests for categorical variables between pa-
tients admitted for any cause or with no hospitaliza-
tion, or for an admission for HF or no hospitalization.
Similar comparisons were made between the same
groups of patients by vital status. Data are presented as
mean SD or percent. Echocardiographic variables are
from a 745-patient substudy. The effect of the ﬁrst
hospitalization for any reason and for HF on the risk
for mortality was determined by Cox regression ana-
lyses with the ﬁrst hospitalization as a time-
dependent variable. A similar analysis was done for
the non-HF hospitalizations, and this group was
composed of patients who did not experience HF ad-
missions during the study. A 30-day readmission was
deﬁned as rehospitalization for any reason within 30
days of discharge from any HF hospitalization. An
overall (time) unadjusted hazard ratio (HR) and an HR
adjusted for established predictors of deaths in the
I-PRESERVE cohort were estimated for each hospital-
ization end point (16). Similarly, because a previous
study (17) had indicated that the risk for dying
decreases with time post-discharge, a Cox model was
used to estimate HRs for several discrete periods
of time after discharge. Furthermore, separate ana-
lyses were done for different causes of death and
the length of stay for the ﬁrst hospitalization. Other
types of deaths were censored in these analyses. The
person-time mortality rates within each discrete time
period were calculated to complement the HRs. In
separate analyses, the ﬁrst hospitalization for either
HF or any cause was considered the index hospi-
talization. Subsequent hospitalizations of any type
after discharge from the index hospitalization were
considered recurrent events. Patients were censored
at the time of death, study termination, or last known
follow-up date.
A 2-sided p value #0.05 was considered to indicate
statistical signiﬁcance in this secondary analysis of
the I-PRESERVE database. Stata version 13 (StataCorp
LP, College Station, Texas) was used for all analyses.
RESULTS
HOSPITALIZATIONS. During a mean follow-up
period of 49.5 months, 2,278 of 4,128 patients (55%)
were hospitalized at least once, and 1,850 patients
were never hospitalized. The patients who were
hospitalized differed from those not hospitalized inmany baseline parameters, including that they were
older; were more likely to have ischemic causes of HF,
histories of diabetes mellitus, or myocardial in-
farctions; had recent HF hospitalizations; had higher
N-terminal pro–brain natriuretic peptide levels, heart
rates, and quality-of-life scores; and lower left ven-
tricular ejection fractions and estimated glomerular
ﬁltration rates (Table 1). A total of 126 patients died
during the initial hospitalization, and among the 2,152
survivors, 1,346 (63%) were readmitted. There were
685 patients (16.6%) hospitalized at least once for a
primary diagnosis of HF, while 3,443 patients were
not. Patients hospitalized for HF differed from those
not hospitalized in being older and more likely
to have histories of previous HF hospitalization, dia-
betes mellitus, and chronic obstructive pulmonary
disease; they also had higher N-terminal pro–brain
natriuretic peptide levels but lower left ventricular
ejection fractions and estimated glomerular ﬁltration
rates (Table 2). A total of 31 patients died during the
ﬁrst admission for HF. Among the 654 surviving pa-
tients, 450 (69%) experienced at least 1 recurrent
admission for any cause.
ANY-CAUSE HOSPITALIZATIONS. There were a total
of 5,863 any-cause hospitalizations in I-PRESERVE.
Of these, 2,278 (39%) were ﬁrst hospitalizations and
61% (3,585 of 5,863) were recurrent hospitalizations.
As seen in Figure 1A, 1,226 (53.8%) of the initial hos-
pitalizations were due to CV causes, 997 (43.8%) were
non-CV hospitalizations, and 55 (2.4%) were for un-
known causes. A primary admission for worsening HF
was the largest subcategory of ﬁrst hospitalizations
(400 admissions, 17.6% of all ﬁrst admissions). CV
procedures were the next largest CV subcategory
(6.1%). Total hospitalizations by category are seen
in Figure 1B. As noted above, there were 5,863 ad-
missions for any cause: 3,141 (53.6%) CV, 2,564
(43.7%) non-CV, and 158 (2.7%) unknown. Worsening
HF was the largest single subcategory, with 1,236
(21.1%) of all hospitalizations. These results are also
seen in Online Table 2.
The distribution of all sequential recurrent hospi-
talizations without regard to the cause of the initial
hospitalization is seen in Online Table 2. For the 1,346
ﬁrst recurrent hospitalizations, 725 (53.9%) were for a
CV cause, and 574 (42.6%) were for a non-CV cause,
and 47 (3.5%) were for unknown causes. Worsening
HF was the most common subcategory, 268 (19.9%).
Subsequent recurrent hospitalizations had a similar
distribution of cause of readmission except for
worsening HF which tended to be increased.
HF HOSPITALIZATIONS. There were 685 patients
with hospitalizations for HF. Among these
TABLE 1 Baseline Characteristics of Patients With and Without
Any-Cause Hospitalization
No Hospitalization
(n ¼ 1,850)
Hospitalization
(n ¼ 2,278)
p
Value
Demographics
Age, yrs 70.1  6.5 72.9  7.1 <0.001
Women 1,177 (63.6%) 1,314 (57.7%) <0.001
White 1,712 (92.5%) 2,147 (94.2%) 0.027
Clinical
NYHA functional class 0.002
II 344 (18.6%) 526 (23.1%)
III 1,459 (78.9%) 1,685 (74.0%)
IV 46 (2.5%) 66 (2.9%)
Heart rate, beats/min 70.8  9.8 72  10.9 <0.001
Systolic BP, mm Hg 136.6  13.6 136.2  16.1 0.353
Diastolic BP, mm Hg 79.9  8.2 77.8  9.6 <0.001
Body mass index, kg/m2 29.3  4.7 29.9  5.7 0.001
Ischemic cause of HF 400 (21.6%) 636 (27.9%) <0.001
Minnesota Living With Heart
Failure Questionnaire score
43 (29–57) 41 (26–59)
Ejection fraction, % 60.1  8.8 58.9  9.4 <0.001
LV mass/BSA, g/m2 83.5  23.1 87.9  23.6 0.019
E/E0 ratio, lateral 9.6  5 9.9  4.1 0.369
LV hypertrophy on ECG 686 (37.1%) 574 (25.2%) <0.001
Left bundle branch block on ECG 138 (7.5%) 198 (8.7%) 0.150
Medical history
Hypertension 1,676 (90.6%) 1,974 (86.7%) <0.001
Myocardial infarction 393 (21.2%) 576 (25.3%) 0.002
PCI or CABG 158 (8.5%) 390 (17.1%) <0.001
Atrial ﬁbrillation 423 (22.9%) 786 (34.5%) <0.001
Diabetes mellitus 412 (22.3%) 722 (31.7%) <0.001
Stroke or TIA 145 (7.8%) 254 (11.2%) <0.001
COPD 104 (5.6%) 287 (12.6%) <0.001
HF hospitalization within 6 months 690 (37.3%) 1,126 (49.4%) <0.001
Laboratory
Hemoglobin, g/dl 14.1  1.4 13.9  1.6 <0.001
Anemia, <13 if male,
<12 if female
151 (8.4%) 321 (14.5%) <0.001
Creatinine, mg/dl 0.9  0.3 1.1  0.3 <0.001
GFR, ml/min/1.73 m2 77  21.3 69  22.6 <0.001
CKD, GFR <60 ml/min/1.73 m2 402 (22.1%) 847 (37.6%) <0.001
Sodium, mEq/l 139.7  2.8 139.4  3.2 <0.001
Potassium, mEq/l 4.4  0.5 4.4  0.5 0.544
NT-proBNP, pg/ml 237 (104–637) 465 (180–1,204) <0.001
Continued on the next page
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432patients, there were 551 readmissions, for a total of
1,236 HF hospitalizations. As seen in Figure 1C, 306
(68%) of the ﬁrst recurrent hospitalizations were for
primary CV diagnoses, while 138 (30%) were for pri-
mary non-CV causes, with 6 (1.3%) of unknown cause.
Worsening HF was the primary diagnosis in 189 (42%)
of these ﬁrst recurrent events, and they accounted for
approximately the same proportion of second and
subsequent recurrent events (Online Table 3). There
were 1,371 recurrent hospitalizations for any cause
after an initial HF event, 866 (63.2%) were CV,
482 (35.2%) were non-CV, and 1.7% were unknown.
There were 551 (40.2%) HF rehospitalizations(Figure 1D). The distribution of subsequent recurrent
hospitalizations subcategories is seen in Online
Table 3 with a similar pattern of events.
30-DAY READMISSIONS. Of the 1,236 HF hospitali-
zations, 30-day follow-up was available for 1,111
events, because of either death or loss to follow-up.
There were 205 (18%) readmissions within 30 days
of HF hospitalizations. Of these, 150 readmissions
(73%) were due to CV causes, with 99 (48%) being due
to worsening HF (Online Table 4, Online Figure 1).
MORTALITY RISK POST-HOSPITALIZATION. Morta l i ty
r i sk post–any-cause hosp i ta l i zat ion . There were
2,278 patients with hospitalizations for any reason:
126 (5.5%) died during the initial hospitalization, and
another 603 (26.5%) died by the end of the trial,
resulting in 32% deaths (729 of 2,278) in this group
and 28% (603 of 2,152) among those who were dis-
charged. Among the 1,850 patients who did not have
hospitalizations during the study, 152 (8.2%) died.
The complete list of baseline characteristics of pa-
tients hospitalized versus never hospitalized and vi-
tal status is shown in Online Table 1A. Patients who
died after hospitalization differed from those who did
not in a number of characteristics associated with
worse outcomes.
After discharge, the unadjusted HR was 8.53
(95% conﬁdence interval [CI]: 7.06 to 10.31) and the
adjusted HR was 5.32 (95% CI: 4.21 to 6.73) for all-
cause mortality compared with those never hospi-
talized for any reason (Table 3). The overall death
rate in the patients after any hospitalization was
11.1 deaths/100 patient-years [PYs], while in those
never hospitalized, it was 1.3 deaths/100 PYs. The risk
for mortality and the incident mortality rate were
highest in the ﬁrst month and decreased thereafter,
although they remained signiﬁcantly elevated th-
roughout the entire follow-up period in both the
adjusted and unadjusted analyses (Table 4).
Morta l i ty r i sk post–HF hosp i ta l i zat ion . During I-
PRESERVE, among the 685 patients with at least 1
hospitalization for HF, 31 (4.5%) died during the
initial hospitalization and another 270 (39.4%) died
by the end of the trial, resulting in 43.9% (301 of 685)
deaths in this group and 41% (270 of 654) among
those who were discharged. In contrast, there were
3,443 patients without HF hospitalizations, and 580
of these patients (16.8%) died during the study. Those
hospitalized for HF differed in many baseline char-
acteristics from those not hospitalized, as indicated
above, and those who died differed from those alive
in both subgroups (Online Table 1B). Among patients
hospitalized for HF, those who died differed in a
number of characteristics, including that they were
TABLE 1 Continued
No Hospitalization
(n ¼ 1,850)
Hospitalization
(n ¼ 2,278)
p
Value
Medications
Diuretic agents 1,507 (81.5%) 1,911 (84.0%) 0.037
Loop 799 (43.2%) 1,351 (59.4%) <0.001
Thiazide 877 (47.4%) 678 (29.8%) <0.001
Spironolactone 231 (12.5%) 402 (17.7%) <0.001
ACE inhibitors 445 (24.1%) 588 (25.8%) 0.193
Digoxin 205 (11.1%) 356 (15.6%) <0.001
Beta-blockers 1,118 (60.5%) 1,309 (57.5%) 0.055
Antiarrhythmic agents 120 (6.5%) 239 (10.5%) <0.001
Calcium-channel blockers 784 (42.4%) 853 (37.5%) 0.001
Nitrates 439 (23.7%) 669 (29.4%) <0.001
Lipid-lowering agents 524 (28.3%) 755 (33.2%) 0.001
Values are mean  SD, n (%), or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; BP ¼ blood pressure; BSA ¼ body surface area;
CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive
pulmonary disease; ECG ¼ electrocardiography; GFR ¼ glomerular ﬁltration rate; HF ¼ heart
failure; LV ¼ left ventricular; NT-proBNP¼ N-terminal pro–brain natriuretic peptide; NYHA¼ New
York Heart Association; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic
attack.
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433older, had higher N-terminal pro–brain natriuretic
peptide levels, had higher heart rates, had lower left
ventricular ejection fractions, and had worse renal
function compared with those who survived.
The overall (time) unadjusted HR for subsequent
all-cause mortality in patients discharged after HF
hospitalization, compared with a concurrent group
that was never hospitalized for HF, was 4.86 (95%
CI: 4.19 to 5.76) and was 2.93 (95% CI: 2.40 to 3.57)
when adjusted for baseline predictors of mortality (16)
(Table 3). The overall mortality rate post–HF hospi-
talization was 19.3 deaths/100 PYs. The adjusted
mortality risk and incident mortality rate were highest
in the ﬁrst month (9.39 and 46 per 100 PYs, respec-
tively) with a subsequent decrease, although the risk
for dying remained 2 to 3 times higher until the end of
follow-up (Table 4). For those not hospitalized for HF,
the mortality rate was 3.8 deaths/100 PYs.
Longer duration of the initial HF hospitalization
was associated with increased risk for mortality post-
discharge compared with shorter hospitalizations
(Figure 2). Patients with HF hospitalizations were at
particularly high risk for subsequent HF death. The
HRs for different modes of death are graphically dis-
played in Figure 3. The full analysis on mode of death
is available in the Online Appendix.
Mortality risk post–non-HF hospitalizations. Because
the entire any-cause hospitalization cohort included
patients with HF admissions but the majority of pa-
tients were hospitalized for non-HF reasons, we
analyzed for mortality after non-HF events and
excluded patients who had HF hospitalizations at any
point. There were 1,593 patients with only non-HF
hospitalizations: 109 (6.8%) died during the initial
hospitalization, and another 319 died by the end of
the trial, resulting in 27% deaths (428 of 1,593) in this
group and 21% (319 of 1,484) among those who were
discharged.
After discharge from the ﬁrst hospitalization for a
non-HF reason, the unadjusted HR was 6.55 (95% CI:
45.32 to 8.07), and the adjusted HR was 4.25 (95% CI:
3.27 to 5.32) for all-cause mortality compared with
the group that was never hospitalized for a non-HF
cause (Table 3). The overall death rate in the pa-
tients after non-HF hospitalization was 8.73 deaths/
100 PYs. The risk for mortality and the incident
mortality rate were again highest in the ﬁrst month
and decreased by 6 months, although they remained
signiﬁcantly elevated throughout the entire follow-
up period in both the adjusted and unadjusted ana-
lyses (Table 4).
CUMULATIVE MORTALITY POST HF, NON-HF, AND
NO HOSPITALIZATION. Figure 4 displays a Kaplan-
Meier curve for cumulative mortality incidence forsubjects after HF or non-HF hospitalization and also
for those never hospitalized since randomization.
DISCUSSION
In I-PRESERVE, we also found that 55% of patients
experienced at least 1 hospital admission, and the
majority of hospitalized patients who survived the
admission (63%) were readmitted. CV hospitalizations
were more common than those for non-CV causes.
Whereas HF hospitalizations were the most com-
mon type of CV event, they were a minority of all
hospitalizations (w20%), whether they were the
ﬁrst or subsequent hospitalizations. However, after
HF hospitalization, more recurrent events were for
HF (w40%). During the 30 days after discharge,
nearly one-half of readmissions were for HF.
In examining post-hospitalization mortality, we
found that patients with HFpEF were at high risk for
mortality after any hospitalization. The risk was
highest early after discharge and was independent of
measured prognostic variables available in this data-
base. We observed the highest post-hospitalization
mortality event rates in those admitted primarily for
HF, but those hospitalized for non-HF reasons also
experienced substantial mortality risk. Patients who
were not hospitalized for any reason had a low mor-
tality rate.
HOSPITALIZATIONS IN HFpEF. While it is known
that HF patients are frequently hospitalized, the pri-
mary reasons for these events have not been well
deﬁned, particularly in HFpEF. HF registries and
TABLE 2 Baseline Characteristics of Patients With and Without HF Hospitalizations
No HF
Hospitalization
(n ¼ 3,443)
HF
Hospitalization
(n ¼ 685)
p
Value
Demographics
Age, yrs 71.1  6.9 74.1  6.9 <0.001
Women 2,083 (60.5%) 408 (59.6%) 0.647
White 3,208 (93.2%) 651 (95%) 0.071
Clinical
NYHA functional class 0.003
II 682 (19.8%) 188 (27.5%)
III 2,681 (77.9%) 463 (67.6%)
IV 78 (2.3%) 34 (5.0%)
Heart rate, beats/min 71  10.3 73.5  11.1 <0.001
Systolic BP, mm Hg 136.5  14.8 135.5  15.8 0.113
Diastolic BP, mm Hg 79.1  8.9 76.8  9.6 <0.001
Body mass index, kg/m2 29.5  5.1 30.2  6 0.002
Ischemic cause of HF 842 (24.5%) 194 (28.3%) 0.033
Minnesota Living With Heart
Failure Questionnaire score
41 (27–57) 46 (30–63) <0.001
Ejection fraction, % 59.8  9.1 57.7  9.1 <0.001
LV mass/BSA, g/m2 84.2  22.8 95.4  25.3 <0.001
E/E0 ratio, lateral 9.8  4.6 9.8  4.1 0.917
LV hypertrophy on ECG 1,079 (31.3%) 181 (26.4%) 0.011
Left bundle branch block on ECG 268 (7.8%) 68 (9.9%) 0.061
Medical history
Hypertension 3,051 (88.6%) 599 (87.4%) 0.382
Myocardial infarction 791 (23%) 178 (26%) 0.089
PCI or CABG 433 (12.6%) 115 (16.8%) 0.003
Atrial ﬁbrillation 880 (25.6%) 329 (48.0%) <0.001
Diabetes mellitus 872 (25.3%) 262 (38.2%) <0.001
Stroke or TIA 317 (9.2%) 82 (12.0%) 0.025
COPD 283 (8.2%) 108 (15.8%) <0.001
HF hospitalization within 6 months 1,355 (39.4%) 461 (67.3%) <0.001
Laboratory
Hemoglobin, g/dl 14.1  1.5 13.7  1.6 <0.001
Anemia, <13 if male,
<12 if female
343 (10.2%) 129 (19.3%) <0.001
Creatinine, mg/dl 1  0.3 1.1  0.4 <0.001
GFR, ml/min/1.73 m2 74.2  22.2 64.4  21.7 <0.001
CKD, GFR <60 ml/min/1.73 m2 941 (27.7%) 308 (45.5%) <0.001
Sodium, mEq/l 139.6  2.9 139.3  3.2 0.02
Potassium, mEq/l 4.4  0.5 4.5  0.5 0.25
NT-proBNP, pg/ml 287 (119–797) 852.5 (323–1,778) <0.001
Medications
Diuretic agents 2,783 (80.9%) 635 (92.7%) <0.001
Loop 1,631 (47.4%) 519 (75.8%) <0.001
Thiazide 1,383 (40.2%) 172 (25.1%) <0.001
Spironolactone 452 (13.1%) 181 (26.4%) <0.001
ACE inhibitors 846 (24.6%) 187 (27.3%) 0.135
Digoxin 414 (12.0%) 147 (21.5%) <0.001
Beta-blockers 2,030 (59%) 397 (58%) 0.608
Antiarrhythmic agents 255 (7.4%) 104 (15.2%) <0.001
Calcium-channel blockers 1,383 (40.2%) 254 (37.1%) 0.127
Nitrates 895 (26%) 213 (31.1%) 0.006
Lipid-lowering agents 1,072 (31.2%) 207 (30.2%) 0.626
Values are mean  SD, n (%), or median (interquartile range).
Abbreviations as in Table 1.
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434other observational databases have reported on
mortality and cause of hospitalizations during follow-
up but do not provide detailed data on adjudicated
causes of hospitalizations (12,13,18). Clinical trials are
often designed to look at hospitalizations, particu-
larly for HF as part of a composite endpoint, as a time
to ﬁrst event analysis. Thus, other causes of hospi-
talization are often not reported and subsequent
hospitalizations not adjudicated. Further most pre-
vious reports on the hospitalization burden in HF
have been largely from patients with a reduced ejec-
tion fraction (HFrEF) which also found that the most
hospitalizations were for CV causes, with the majority
of these for HF (19–22). However, only 2 HFrEF
studies, EVEREST (Efﬁcacy of Vasopressin Antago-
nism in Heart Failure Outcome Study with Tolvaptan)
and COPERNICUS (Carvedilol Prospective Random-
ized Cumulative Survival) have presented detailed
description of CV hospitalizations (21,22). Not sur-
prisingly in these advanced HFrEF patients, HF hos-
pitalizations were the predominant component of CV
hospitalizations: In EVEREST, HF hospitalizations
were 46% of any cause and 76% of CV; while in
COPERNICUS (placebo arm) HF hospitalizations were
53% of any cause and 64% of CV. Other CV causes
were infrequent. Treatments that have reduced hos-
pitalizations in studies of HFrEF have showed sig-
niﬁcant reduction in cardiovascular hospitalizations,
which in turn has been due largely to a reduction in
the common HF hospitalizations.
As noted in this paper in a HFpEF cohort, CV hos-
pitalizations were also the majority of events and
there was a wide range of CV causes with HF hospi-
talizations a lower proportion than in HFrEF. The
only previously published data describing causes of
hospitalization in an HFpEF cohort are the unadju-
dicated results from the ancillary DIG (Digitalis
Investigation Group) study that only described the
ﬁrst hospitalization of each type, and reported a wide
range of CV hospitalizations consistent with the cur-
rent data (4). The population enrolled in I-PRESERVE
was, as in HFpEF epidemiologic databases, an older
cohort with multiple CV risk factors, particularly hy-
pertension, as well as multiple non-CV comorbidities.
Not surprisingly, hospitalized patients had more
comorbidities and more unfavorable physiologic
variables than those not hospitalized, including those
previously reported to be associated with worse out-
comes in I-PRESERVE (9). In considering the compo-
sition of the hospitalizations, it is notable that
many CV causes were infrequent despite the age and
comorbidities present. For example, while it might be
expected that events related to cardiac ischemia
would be infrequent given the modest numbers with
FIGURE 1 First and Total Hospitalizations and First and Total Readmissions After HF Hospitalization: Primary Causes
(A) For the 2,278 ﬁrst hospitalizations, the subcategories of the 1,226 (53.8%) cardiovascular hospitalizations are shown. The 997 (43.8%) noncardiovascular ﬁrst
hospitalizations are shown as a single category. (B) For the 5,863 total hospitalizations, the subcategories of the 3,141 (53.6%) cardiovascular hospitalizations are shown.
The 2,564 (43.7%) noncardiovascular total hospitalizations are shown as a single category. (C) For the 551 rehospitalizations after heart failure (HF) events, the sub-
categories of the 306 (68%) cardiovascular hospitalizations are shown. The 138 (30%) noncardiovascular ﬁrst readmissions are shown as a single category. (D) For the
1,371 total rehospitalizations after HF events, the subcategories of the 866 (63.2%) cardiovascular hospitalizations are shown. The 138 (30%) noncardiovascular ﬁrst
readmissions are shown as a single category.
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435a previous myocardial infarction or ischemic etiology,
it is perhaps surprising that hospitalizations due to
atrial arrhythmias or cerebrovascular accidents were
also relatively uncommon. CV procedures were the
most frequent non HF admission subcategory and
these were <6% of recurrent events. The wide range
of CV hospitalizations and common non-CV hospi-
talizations, together with a lower proportion of HF
events, make total or CV hospitalization reduction
difﬁcult to achieve in a cohort with HFpEF.
Nonetheless, HF was the most common single
cause of hospitalization in the overall I-PRESERVE
cohort, with a proportion similar to reports fromCHARM (Candesartan in Heart Failure Assessment of
Reduction in Mortality and Morbidity) Preserved (5)
as well as the ancillary DIG study (4). These events
would be a target for therapy. However, in this overall
cohort of patients, who were clinically stable out-
patients when enrolled, over a mean follow-up of
more than 49 months, only 16% experienced HF
hospitalizations, which represented only 21% of total
events. Therefore, an intervention to reduce HF ad-
missions would require a large clinical trial with a
long follow-up time. A recent approach to the chal-
lenge of such clinical trials has been statistical ana-
lyses, which have included recurrent hospitalizations
TABLE 3 Unadjusted and Adjusted Risk for All-Cause Mortality After Discharge From HF, Any-Cause, or Non-HF Hospitalization
Any-Cause Hospitalization HF Hospitalization Non-HF Hospitalization
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Model 1: unadjusted (n ¼ 4,128)
Discharge for ﬁrst hospitalization for HF 8.53 (7.06–10.31) <0.001 4.86 (4.19–5.63) <0.001 6.55 (5.32–8.07) <0.001
Model 2: adjusted (n ¼ 2,722)
Discharge for ﬁrst hospitalization for HF 5.32 (4.21–6.73) <0.001 2.93 (2.40–3.57) <0.001 4.25 (3.27–5.52) <0.001
Hospitalized for HF in past 6 months 1.06 (0.88–1.29) 0.521 1.02 (0.85–1.23) 0.829 1.24 (0.97–1.59) 0.079
Age, per 10-yr increase 1.39 (1.20–1.60) <0.001 1.47 (1.28–1.68) <0.001 1.53 (1.28–1.84) <0.001
LVEF, per 5% decrease 1.07 (1.02–1.13) 0.010 1.07 (1.02–1.13) 0.009 1.07 (1.00–1.14) 0.06
Heart rate, per 5 beats/min increase 1.08 (1.04–1.12) <0.001 1.07 (1.03–1.11) 0.001 1.05 (0.99–1.10) 0.096
Minnesota Living With Heart Failure
Questionnaire score, per 5-U increase
1.03 (1.01–1.05) 0.004 1.02 (1.00–1.04) 0.021 1.04 (1.01–1.07) 0.005
GFR, per 5 ml/min/1.73 m2 decrease 0.99 (0.97–1.01) 0.468 1.00 (0.98–1.02) 0.826 0.97 (0.94–1.00) 0.023
NT-pro-BNP (log) 1.46 (1.35–1.58) <0.001 1.39 (1.29–1.50) <0.001 1.52 (1.37–1.69) <0.001
Neutrophils (log) 1.36 (1.04–1.76) 0.023 1.50 (1.17–1.92) 0.001 1.59 (1.11–2.27) 0.012
Ischemic cause of HF 1.12 (0.89–1.40) 0.343 1.21 (0.98–1.51) 0.081 1.08 (0.82–1.44) 0.573
History of myocardial infarction 1.23 (0.98–1.55) 0.078 1.19 (0.96–1.49) 0.120 1.57 (1.18–2.07) 0.002
History of diabetes mellitus 1.38 (1.14–1.68) 0.001 1.47 (1.22–1.76) <0.001 1.59 (1.24–2.04) <0.001
History of COPD 1.15 (0.88–1.50) 0.300 1.18 (0.91–1.53) 0.0224 1.47 (1.03–2.08) 0.032
Multivariate models are adjusted per models in Komajda et al. (16).
CI ¼ conﬁdence interval; LVEF ¼ left ventricular ejection fraction; other abbreviations as in Table 1.
TABLE 4
Time
Model 1: u
0–1 mon
1–3 mon
3–6 mo
6–12 mo
12–24 m
>24 mo
No hosp
Model 2: a
0–1 mon
1–3 mon
3–6 mo
6–12 mo
12–24 m
>24 mo
No hosp
Multivariate
PY ¼ pati
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436(22,23). Alternatively, patients hospitalized for HF
might provide an attractive target for an intervention,
given that a greater proportion of HF events as sug-
gested by the present data in which 40% of rehospi-
talizations were for this cause.
This study also examined recurrent hospitaliza-
tions in the 30-day period after HF admission. ThisUnadjusted and Adjusted Risk for All-Cause Mortality by Time Since Dis
Since Discharge
Any-Cause Hospitalization
HR (95% CI)
Deaths
(Rate/100 PYs) HR (9
nadjusted (n ¼ 4,128)
ths 17.09 (11.99–24.37) 39 (22.4) 12.59 (8
ths 11.56 (8.36–15.98) 50 (14.9) 7.89 (5.
nths 11.13 (8.34–14.83) 71 (14.8) 4.78 (3
nths 6.59 (4.97–8.75) 76 (8.5) 3.49 (2.
onths 7.43 (5.86–9.42) 154 (10.2) 4.19 (3
nths 7.03 (5.54–8.92) 213 (10.4) 4.63 (3
italization 1.0 (reference group) 152 (1.3) 1.0 (refere
djusted (n ¼ 2,722)
ths 11.45 (7.18–18.25) 9.39 (5.
ths 8.36 (5.52–12.64) 6.37 (4.
nths 7.48 (5.18–10.81) 3.08 (1
nths 4.08 (2.84–5.86) 2.01 (1.
onths 4.96 (3.70–6.65) 2.65 (1.
nths 4.00 (2.98–5.36) 2.40 (1
italization 1.0 (reference group) 1.0 (refere
models are adjusted per models in Komajda et al. (16). All p values <0.001 except as indi
ent-year; other abbreviations as in Tables 1 and 2.has become an important hospital performance mea-
sure. There have been no previous reports from a
clinical trial or registry to provide insight on 30-day
readmission rates in a HFpEF population and only
1 from a HFrEF clinical trial: the A-HeFT (African-
American Heart Failure Trial); 23.6% 30-day read-
mission rate after the ﬁrst HF hospitalization in thecharge After HF, Any-Cause, or Non-HF Hospitalization
HF Hospitalization Non-HF Hospitalization
5% CI)
Deaths
(Rate/100 PYs) HR (95% CI)
Deaths
(Rate/100 PYs)
.35–18.97) 24 (46) 15.73 (10.42–23.74) 27 (22.5)
39–11.56) 28 (28.7) 10.53 (7.23–15.33) 34 (14.6)
.17–7.20) 24 (17.6) 11.10 (8.04–15.33) 51 (15.5)
44–5.00) 32 (12.9) 4.91 (3.44–7.00) 40 (6.6)
.24–5.42) 67 (16.7) 5.44 (4.09–7.25) 78 (7.7)
.67–5.83) 95 (20.4) 4.04 (3.01–5.41) 89 (6.6)
nce group) 580 (3.8) 1.0 (reference group) 152 (1.4)
72–15.42) 10.52 (5.97–18.51)
10–9.90) 6.61 (3.87–11.26)
.85–5.13) 7.88 (5.15–12.07)
27–3.18)* 3.52 (2.24–5.55)
92–3.64) 3.75 (2.61–5.41)
.79–3.22) 2.69 (1.87–3.87)
nce group) 1.0 (reference group)
cated. *p ¼ 0.003.
FIGURE 2 Duration of HF Hospitalization and Relation to Subsequent Mortality
Inﬂuence of time from discharge and length of heart failure (HF) hospital stay on death rates after discharge from a hospitalization for HF.
J A C C : H E A R T F A I L U R E V O L . 3 , N O . 6 , 2 0 1 5 Carson et al.
J U N E 2 0 1 5 : 4 2 9 – 4 1 Morbidity and Mortality in HFpEF
437placebo group (24). The I-PRESERVE data also in-
dicates a slightly lower readmission rate (18%) but
there still was a high proportion of 30-day read-
missions due to CV and HF cause.FIGURE 3 Mode of Death After a Heart Failure Hospitalization
Hazard ratios of various causes of death after discharge from the hospit
discharge adjusted for other baseline predictors of all-cause mortality. CPOST-HOSPITALIZATION MORTALITY IN HFpEF. Our
ﬁndings demonstrate that patients with HFpEF
enrolled as stable outpatients in a randomized
clinical trial have substantial mortality risk afteral for heart failure hospitalization at various time intervals after
V ¼ cardiovascular.
FIGURE 4 Cumulative Mortality Post-Hospitalization (HF and Non-HF) and No Hospitalization
Mortality by Kaplan-Meier analysis after a hospitalization for heart failure (HF), not for heart failure (from time of admission), or from
randomization for patients with no hospitalization for any cause.
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438hospitalization for any cause, particularly after HF
admission. There are no comparable data from a
randomized clinical trials involving patients with
HFpEF, but there have been 2 previous reports from
predominantly or entirely HFrEF studies that have
used a similar time-dependent statistical methodol-
ogy. Both SHIFT (Systolic Heart Failure Treatment
With the IF Inhibitor Ivabradine Trial) (25) and
CHARM (26) found that mortality risk was highest
early after HF hospitalization and decreased over
time, though it remained substantially elevated
compared with patients never hospitalized or yet to
be hospitalized. The methodology in the present
analysis differs slightly in that the patient time before
a hospitalization, so-called immortal time, was not
included in the calculation of risk ratios, but the
pattern of risk over time is consistent with these
previous studies. In considering post–HF hospitali-
zation mortality rates, those in I-PRESERVE are sub-
stantially lower than the unadjusted event rates
reported from the HFrEF cohort in SHIFT, a ﬁnding
that would be consistent with the data from the
recent MAGGIC (Meta-Analysis Global Group in
Chronic Heart Failure) meta-analysis of cohort
studies and clinical trial databases (8). The CHARM
Program publication did not provide separate
mortality rates for its HFpEF cohort (37% of total
patients) or provide event rates for the overallcohort (18). The only previous reports of post–HF
hospitalization mortality results in a HFpEF cohort
have come from registries. For example, in the
DIAMOND (Danish Investigations of Arrhythmia and
Mortality) registry, the post–HF hospitalization mor-
tality rate was 19% at 1 year (27).
Why were patients hospitalized for HF in I-PRE-
SERVE at such high risk? The baseline characteristics
of those hospitalized for HF, including both comor-
bidities and indicators of more severe disease,
differed from those not hospitalized, and those who
died differed further from those who did not. How-
ever, even after adjustment for the baseline pre-
dictors associated with mortality risk in the overall
I-PRESERVE database, the HF hospitalization event
remained independently associated with a worse
outcome. This may seem surprising, because HF
hospitalization could be due to progression of the
disease but also could be due to other causes, such as
nonadherence, poor follow-up, or inadequate ther-
apy. Although the present analysis does not provide a
good explanation for the high post–HF hospitalization
mortality risk, the mode-of-death analysis showed a
particularly high risk for HF death early after
discharge, suggesting worsening of the disease pro-
cess in these subjects. The hospital experience itself
may contribute, as noted below. The ﬁnding that an
HF hospitalization is a salient event in a patient’s
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439course, which requires careful post-discharge atten-
tion, has been reported in numerous HFrEF databases
(4,23,26), but our data extend these ﬁndings to pa-
tients with HFpEF, indicating a need for careful
attention early after discharge, although speciﬁc
therapies for this period of high risk have not been
established.
We also found a high risk for death after a
nonelective hospitalization for any cause, with a
similar pattern to that observed after HF admission.
However, these ﬁndings need to be interpreted with
caution, because both initial and subsequent HF
hospitalizations were included in all-cause hospitali-
zations and therefore would affect the risk of the time
intervals and event rates of the all-cause events. For
this reason, we have included an analysis of patients
who were hospitalized for any cause but not for HF.
We observed a lower risk for mortality after these
hospitalizations than that observed after HF hospi-
talization, but the event rate for these patients is still
substantially higher than that for patients without
hospitalizations. The excess risk associated with any
hospitalization, HF or not, may be related to factors
associated with the in-hospital experience. As noted
by Krumholz (28), these include alterations in cogni-
tive and physiologic function, including decondi-
tioning and malnutrition, which then also affect the
early post-discharge phase. These factors are sug-
gested in the data of the current study, in which
prolonged HF hospitalization was associated with the
highest early post-discharge mortality risk. An older
population is particularly vulnerable to what has been
described as the “post-hospital syndrome.” This
excess risk also points to a need for careful attention
to the treatment of comorbidities in HFpEF, as sug-
gested by Ather et al. (29) as part of a strategy to
reduce overall mortality risk.
Our study also identiﬁed a group of patients at
lower mortality risk who were not hospitalized for HF
and an even lower risk group who were never hospi-
talized for any reason. The patients not hospitalized
for HF differed from those hospitalized for HF in
many characteristics, as did the group hospitalized
for any reason compared with those never hospital-
ized. The ﬁnding that most patients in I-PRESERVE
were not hospitalized for HF, and many were not
hospitalized at all, indicates that some subjects may
have a mild variant of the disease, and others may not
have HF at all. Although the I-PRESERVE inclusion
criteria required the presence of signs and symptoms
as well as structural and functional abnormalities,
many of these features, such as shortness of breath
and ankle edema, are nonspeciﬁc, underscoring the
difﬁculty in diagnosing HFpEF (30).IMPLICATIONS. The ﬁnding that hospitalized pa-
tients are at higher risk than those not hospitalized is
not surprising, although this has not been previously
quantitated for non-HF hospitalization or in the
HFpEF population. This underscores the need to
focus more on the clinical care of such hospitalized
patients. These data further support the importance
of enrolling patients during acute decompensated
HF hospitalizations in clinical trials of patients with
HFpEF, as the enrollment of stable outpatients is
more likely to be dominated by low-risk subjects.
This problem is magniﬁed in HFpEF because of the
lack of speciﬁcity of the clinical symptoms and
ﬁndings that are often present. Our data suggest that
enrolling subjects during their HF hospitalizations
would result in a cohort with a high subsequent risk
for HF hospitalizations and mortality. It is important
to note that the HF hospitalizations in the I-PRE-
SERVE database were carefully adjudicated by an
event committee. It should also be emphasized that
when HF hospitalization is used as an inclusion cri-
terion in clinical trials, the deﬁnition of HF hospi-
talization needs to be carefully considered. This
might avoid the difﬁculties encountered in the
TOPCAT (Treatment of Preserved Cardiac Function
Heart Failure with an Aldosterone Antagonist) study,
in which a low-risk cohort was reported in those
entry criteria pathway that was a history of hospi-
talization with a “a major component of the care
provided” (10,31).
STRENGTHS AND LIMITATIONS. We studied well-
characterized patients in the I-PRESERVE trial, the
largest study of patients with HFpEF, which had
adjudicated data and excellent follow-up data. In
addition, we were able to adjust for prognostic vari-
ables previously described in this population. How-
ever, this was a secondary analysis of data from
a randomized controlled trial, and patients were
deﬁned according to events occurring after enroll-
ment. Furthermore, some of the baseline charac-
teristics may have changed by the time of the
hospitalization. The inclusion and exclusion criteria,
including a history of hospitalization within 6 months
and limitations on non-CV comorbidities, may have
contributed to the distribution of hospitalizations
over the duration of the study, although the propor-
tion of hospitalizations for HF is similar to that in a
recent community-based report of hospitalizations
after a new diagnosis of HF (17). Judgments about the
mode of death can be inﬂuenced by a recent HF
hospitalization. Non-CV hospitalizations did not un-
dergo full committee review, as these events were
initially assessed by the sponsor, on the basis of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Hos-
pitalizations for HF represent a minority of the overall
hospitalization burden in patients with HFpEF. How-
ever, there is a high post-hospitalization mortality risk
after these events, and subsequent hospitalizations
are more likely to be for HF. These patients need
careful attention post-hospitalization, particularly
early, when risk is highest. Additionally, patients
admitted for non-HF causes also are at substantial risk
for subsequent mortality and therefore also require
careful follow-up with attention to comorbidities.
Finally, patients with the diagnosis of HFpEF but not
requiring hospitalization are at low mortality risk.
TRANSLATIONAL OUTLOOK: Clinical trials in
HFpEF have been hampered by low event rates, due
partly to large proportions of enrolled subjects who do
not experience outcomes such as hospitalizations and
death. This may indicate a mild version of the disease or
an inaccurate diagnosis. A clinical trial composed of
subjects admitted for HF would have the advantage of
greater certainty in the diagnosis of a condition that can
be difﬁcult to diagnose correctly and a high event rate,
including death and recurrent HF hospitalizations.
Better understanding of patients with HFpEF who do
not experience clinical events is necessary in consid-
ering large clinical trials that enroll stable outpatients.
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440serious adverse events reports, and then reviewed by
the events committee chair, who sent potential CV
hospitalizations to review.
CONCLUSIONS
In the HFpEF population of I-PRESERVE, hospitali-
zations were common, and the majority of patients
were readmitted. CV causes for hospitalization were
most common, but non-CV hospitalizations were
frequent, as both ﬁrst and recurrent events. After
an initial HF hospitalization, a greater proportion of
recurrent admissions were due to HF, particularly
during the initial 30-day interval. Additionally, pa-
tients hospitalized for any reason but particularly for
HF were at high risk for subsequent death. Sub-
stantial post-hospitalization mortality risk was pre-
sent also in patients with non-HF hospitalizations,
suggesting a need for careful attention to comorbid
conditions. These ﬁndings support the need for
intensive follow-up in the early post-discharge time
period. The outcomes after a HF hospitalization also
suggest that this would be an optimal group in
which to test interventions in future HFpEF clinical
trials.
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